Allergan, Inc. News Headlines

AGN 
$211.95
*  
1.83
0.87%
Get AGN Alerts
*Delayed - data as of Dec. 26, 2014  -  Find a broker to begin trading AGN now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Avanir Pharmaceuticals Shoots Up on Positive AVP-923 Data - Analyst Blog
9/16/2014 2:50:00 PM - Zacks.com


In the news: GM to pay for 19 deaths, Boeing teams up with Bezos and more
9/16/2014 8:16:00 AM - Market Intelligence Center


NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog
9/15/2014 6:05:00 PM - Zacks.com


Alnylam Expands Pipeline with Preeclampsia Drug ALN-AGT - Analyst Blog
9/15/2014 6:00:00 PM - Zacks.com


QLT Unveils Positive Retreatment Study Data - Analyst Blog
9/15/2014 5:50:00 PM - Zacks.com


Novartis Presents Positive Data on Lucentis and Jetrea - Analyst Blog
9/15/2014 4:35:00 PM - Zacks.com


Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog
9/15/2014 4:20:00 PM - Zacks.com


Eli Lilly's Cyramza Scores in Colorectal Cancer Study - Analyst Blog
9/15/2014 3:30:00 PM - Zacks.com


Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada - Analyst Blog
9/12/2014 4:30:00 PM - Zacks.com


Will Allergan's Board Be Revamped to Aid Valeant Buyout? - Analyst Blog
9/12/2014 4:25:00 PM - Zacks.com


Novo Nordisk's Saxenda Gets Positive Opinion for Obesity - Analyst Blog
9/12/2014 4:10:00 PM - Zacks.com


AbbVie's Humira Positive in Phase III Skin Disease Study - Analyst Blog
9/12/2014 4:05:00 PM - Zacks.com


Abbott Labs (ABT) to Repurchase Shares for $3B - Analyst Blog
9/12/2014 3:50:00 PM - Zacks.com


Eli Lilly/Boehringer's Insulin Biosimilar Gains EU Approval - Analyst Blog
9/11/2014 5:45:00 PM - Zacks.com


Novartis Presents Data on Multiple Sclerosis Drug Gilenya - Analyst Blog
9/11/2014 4:55:00 PM - Zacks.com


Auxilium Pharmaceuticals to Restructure, Cut Jobs by 30% - Analyst Blog
9/10/2014 3:35:00 PM - Zacks.com


Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog
9/10/2014 3:30:00 PM - Zacks.com


Peregrine Pharmaceuticals' Q1 Loss Wider than Expected - Analyst Blog
9/10/2014 8:00:00 AM - Zacks.com


AstraZeneca Presents Unfavorable Benralizumab Study Data - Analyst Blog
9/9/2014 5:35:00 PM - Zacks.com


Glaxo (GSK) Updates on Asthma Candidate Mepolizumab - Analyst Blog
9/9/2014 5:20:00 PM - Zacks.com


Alexion's Asfotase Alfa Gets Japanese Orphan Drug Status - Analyst Blog
9/9/2014 4:30:00 PM - Zacks.com


Roche's (RHHBY) RoActemra Gets EU Approval for Early RA - Analyst Blog
9/9/2014 4:20:00 PM - Zacks.com


Hospira Down on Legal Blow; Court Allows Generic Precedex - Analyst Blog
9/9/2014 3:45:00 PM - Zacks.com


Valeant: One Big Injection
9/9/2014 11:18:00 AM - Seeking Alpha


Keryx Falls after Ferric Citrate's Approval with Warnings - Analyst Blog
9/8/2014 5:05:00 PM - Zacks.com